

References

1. World Health Organization. Obesity and overweight. Accessed [date].
<https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>
2. GBD 2019 Risk Factor Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. *Lancet*. 2020;396:1223-1249.
3. Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? *Int J Obes (Lond)*. 2024. doi:10.1038/s41366-024-01473-y
4. de Vries CEE, Terwee CB, Al Nawas M, et al. Outcomes of the first global multidisciplinary consensus meeting including persons living with obesity to standardize patient-reported outcome measurement in obesity treatment research. *Obes Rev*. 2022;23:e13452.
5. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med*. 2023;389:2221-2232.